Therapeutics against coronavirus disease 2019 (COVID-19) are urgently needed. Granulocyte–macrophage colony-stimulating factor (GM-CSF), a myelopoietic growth factor and pro-inflammatory cytokine, plays a critical role in alveolar macrophage homeostasis, lung inflammation and immunological disease. Both administration and inhibition of GM-CSF are currently being therapeutically tested in COVID-19 clinical trials. This Perspective discusses the pleiotropic biology of GM-CSF and the scientific merits behind these contrasting approaches.

中文翻译：

---

COVID-19 中基于 GM-CSF 的治疗：调和相反的治疗方法。

迫切需要针对 2019 年冠状病毒病 (COVID-19) 的治疗方法。粒细胞 - 巨噬细胞集落刺激因子 (GM-CSF) 是一种骨髓生成生长因子和促炎细胞因子，在肺泡巨噬细胞稳态、肺部炎症和免疫疾病中起关键作用。GM-CSF 的给药和抑制目前正在 COVID-19 临床试验中进行治疗测试。本观点讨论了 GM-CSF 的多效生物学以及这些对比方法背后的科学价值。